BR112014009932A2 - derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos - Google Patents
derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmosInfo
- Publication number
- BR112014009932A2 BR112014009932A2 BR112014009932A BR112014009932A BR112014009932A2 BR 112014009932 A2 BR112014009932 A2 BR 112014009932A2 BR 112014009932 A BR112014009932 A BR 112014009932A BR 112014009932 A BR112014009932 A BR 112014009932A BR 112014009932 A2 BR112014009932 A2 BR 112014009932A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- same
- composition containing
- hdac inhibitors
- hydroxamate derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110111431 | 2011-10-28 | ||
PCT/KR2012/008840 WO2013062344A1 (en) | 2011-10-28 | 2012-10-26 | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014009932A2 true BR112014009932A2 (pt) | 2017-06-13 |
Family
ID=48168087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014009932A BR112014009932A2 (pt) | 2011-10-28 | 2012-10-26 | derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140315889A1 (pt) |
EP (1) | EP2771321A4 (pt) |
JP (1) | JP5771750B2 (pt) |
KR (2) | KR20130047623A (pt) |
CN (1) | CN103906732A (pt) |
BR (1) | BR112014009932A2 (pt) |
CA (1) | CA2846066A1 (pt) |
WO (1) | WO2013062344A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2785720B1 (en) * | 2011-11-29 | 2017-08-09 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
RU2634694C2 (ru) | 2013-04-29 | 2017-11-03 | Чонг Кун Данг Фармасьютикал Корп. | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения |
LT2994465T (lt) * | 2013-05-10 | 2018-10-10 | Karus Therapeutics Limited | Nauji histono deacetilazės inhibitoriai |
JP6388456B2 (ja) * | 2013-06-28 | 2018-09-12 | アルツプロテクト | 神経変性疾患の治療に使用可能なカルボリン化合物 |
PT3080125T (pt) * | 2013-12-12 | 2018-12-14 | Chong Kun Dang Pharmaceutical Corp | Novos derivados de azaindole como inibidores seletivos da histona-desacetilase (hdac) e composições farmacêuticas que compreendem os mesmos |
KR101685639B1 (ko) * | 2014-01-03 | 2016-12-12 | 주식회사 종근당 | 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
WO2015157504A1 (en) * | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
EP3177621B1 (en) | 2014-08-04 | 2021-11-10 | Universität Regensburg | Novel hdac6 inhibitors and their uses |
CN107406417B (zh) | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
CN105168209A (zh) * | 2015-09-21 | 2015-12-23 | 浙江大学 | HDAC1抑制剂在制备调控hepcidin表达药物中的应用 |
CN105348169B (zh) * | 2015-11-16 | 2018-03-30 | 青岛大学 | 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用 |
CN105646371B (zh) * | 2016-01-19 | 2019-10-01 | 浙江大学 | 含异羟肟酸片段的2,4-二芳胺基嘧啶类衍生物及制备和应用 |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
AU2018258338B2 (en) | 2017-04-26 | 2022-07-14 | The Board Of Trustees Of The University Of Illinois | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same |
RU2748835C1 (ru) * | 2017-11-27 | 2021-05-31 | Совет Научных И Прикладных Исследований | Индол(сульфонил)-n-гидроксибензамидные производные в качестве селективных ингибиторов hdac |
KR102078528B1 (ko) | 2018-04-18 | 2020-02-19 | 성균관대학교산학협력단 | 신규한 hdac6 억제제를 이용한 치매 또는 인지장애 예방 또는 치료용 약학적 조성물 |
CN109574936B (zh) * | 2018-11-23 | 2022-02-22 | 沈阳药科大学 | 一种具有hdac6抑制活性的异羟肟酸类化合物及其应用 |
US20230046077A1 (en) | 2019-02-07 | 2023-02-16 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
AU2021297465A1 (en) * | 2020-06-27 | 2023-03-02 | Crescenta Biosciences | Novel cell metabolism modulating compounds and uses thereof |
US20230365554A1 (en) | 2020-07-29 | 2023-11-16 | The Broad Institute, Inc. | Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof |
US20230322767A1 (en) | 2020-07-29 | 2023-10-12 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
CN112724068A (zh) * | 2020-12-30 | 2021-04-30 | 蔡桂坡 | 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用 |
CN115368277B (zh) * | 2022-09-15 | 2024-03-29 | 华侨大学 | 一种含异羟肟酸结构的联苯类化合物及其应用 |
CN115611864A (zh) * | 2022-11-01 | 2023-01-17 | 常州兰陵制药有限公司 | 一种昂丹司琼类化合物及其制备方法与应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559152B2 (en) * | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
ZA200507751B (en) * | 2003-04-07 | 2007-01-31 | Axys Pharm Inc | Novel hydroxamates as therapeutic agents |
GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2008115262A2 (en) * | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
AU2008299896B2 (en) * | 2007-09-10 | 2012-02-02 | Curis, Inc. | Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety |
JP2009191041A (ja) * | 2008-02-18 | 2009-08-27 | Univ Of Tokyo | ヒドロキシメチルケトン誘導体 |
EP2100879A1 (en) * | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
CA2721218C (en) * | 2008-04-15 | 2015-03-24 | Pharmacyclics, Inc. | Selective inhibitors of histone deacetylase |
WO2009137462A2 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
KR101168801B1 (ko) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
EP2456757B1 (en) * | 2009-07-22 | 2019-05-01 | The Board of Trustees of the University of Illionis | Hdac inhibitors and therapeutic methods using the same |
-
2012
- 2012-10-26 BR BR112014009932A patent/BR112014009932A2/pt unknown
- 2012-10-26 CA CA2846066A patent/CA2846066A1/en not_active Abandoned
- 2012-10-26 EP EP12843187.1A patent/EP2771321A4/en not_active Withdrawn
- 2012-10-26 WO PCT/KR2012/008840 patent/WO2013062344A1/en active Application Filing
- 2012-10-26 CN CN201280053111.8A patent/CN103906732A/zh active Pending
- 2012-10-26 KR KR1020120119668A patent/KR20130047623A/ko active Application Filing
- 2012-10-26 US US14/354,206 patent/US20140315889A1/en not_active Abandoned
- 2012-10-26 JP JP2014538712A patent/JP5771750B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-27 KR KR1020150028542A patent/KR101528617B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2771321A4 (en) | 2015-04-08 |
JP5771750B2 (ja) | 2015-09-02 |
KR101528617B1 (ko) | 2015-06-19 |
CN103906732A (zh) | 2014-07-02 |
JP2014530907A (ja) | 2014-11-20 |
KR20130047623A (ko) | 2013-05-08 |
EP2771321A1 (en) | 2014-09-03 |
WO2013062344A1 (en) | 2013-05-02 |
CA2846066A1 (en) | 2013-05-02 |
KR20150028798A (ko) | 2015-03-16 |
US20140315889A1 (en) | 2014-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014009932A2 (pt) | derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos | |
HRP20181647T1 (hr) | Novi spojevi koji su selektivni inhibitori histonske deacetilaze i farmaceutski pripravak koji ih sadrži | |
SMT201700008B (it) | Composizione farmaceutica | |
HRP20181965T1 (hr) | Novi derivati azaindola kao selektivni inhibitori histonske deacetilaze (hdac) i farmaceutski pripravci koji ih sadrže | |
DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
IL233756A (en) | History of hydroxamic acid and their pharmaceutical preparations | |
BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
BR112013020362A2 (pt) | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem | |
DK3181122T3 (da) | Farmaceutisk dasatinib-sammensætning | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
DK2694038T3 (da) | Farmaceutisk sammensætning | |
DK3246018T3 (da) | Farmaceutisk sammensætning | |
BR112015004936A2 (pt) | composição farmacêutica revestida contendo regorafenib | |
BR112013033072A2 (pt) | agente para indução de apoptose e composição farmacêutica | |
BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
BR112013014644A2 (pt) | composição farmacêutica e complexo | |
EE201300005A (et) | Ravimkoostis | |
DK2654736T3 (da) | Hidtil ukendt farmaceutisk sammensætning | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
EP2831067A4 (en) | SMALL MOLECULE MCL-1 INHIBITORS AND USES THEREOF | |
CU24163B1 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
BRPI0917562A2 (pt) | composições farmacêuticas e métodos para estabilizar as mesmas | |
BR112013008615A2 (pt) | formulação farmacêutica para inibidores de desacetilase de histona | |
BR112013023575A8 (pt) | novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes | |
DK3156060T3 (da) | Farmaceutiske sammensætninger og topisk anvendelse deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |